Intellia Therapeutics Announces First Quarter 2021 Financial Results
06 mai 2021 07h30 HE
|
Intellia Therapeutics, Inc.
Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND...
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2021 Earnings and Company Updates
29 avr. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting
27 avr. 2021 16h35 HE
|
Intellia Therapeutics, Inc.
- Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD) CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) --...
Intellia Therapeutics Names Georgia Keresty, Ph.D., M.P.H., to Board of Directors
12 avr. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
Intellia Therapeutics’ Investigational CRISPR Treatment NTLA-2001 Receives European Union Orphan Drug Designation for ATTR Amyloidosis
30 mars 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
Intellia Therapeutics Presents New Data on Expanded Cell Engineering Capabilities Utilizing Base Editors
25 mars 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present the first preclinical data set on its novel cytosine deaminase base editor technology at...
Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium
10 mars 2021 07h30 HE
|
Intellia Therapeutics, Inc.
- Demonstrates the promise of Intellia’s proprietary non-viral delivery system for in vivo genome editing of tissues outside the liver, with applications to inherited blood disorders such as sickle...
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results
25 févr. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
Expects to report initial data from Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloidosis (ATTR), in 2021On track to submit an IND or IND-equivalent in...
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates
18 févr. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021
07 janv. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
Continued advancement of global Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloidosis (ATTR)Anticipates submitting an IND or IND-equivalent in mid-2021...